OLMA · Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals strengthened its Board with the appointment of Dr. Prakash Raman, an experienced biopharma executive, as an independent Class II director effective April 28, 2026. His two decades of leadership, including CEO positions at InduPro Therapeutics and Ribon Therapeutics, and prior roles at Novartis and Flagship Pioneering, position him to contribute to business development and portfolio strategy. This is timely as the company advances palazestrant through two Phase 3 trials with OPERA-01 data expected in fall 2026, and progresses OP-3136 in Phase 1. Compensation aligns with the non-employee director policy, featuring an initial option for 24,150 shares vesting monthly over three years and a partial-year option for 2,911 shares vesting in June 2026, under the 2020 Equity Incentive Plan.